(NASDAQ:SPPI) NEW YORK, Sept. 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the "Class Period"), of the important...
(NASDAQ:SPPI) SAN FRANCISCO, Sept. 4, 2025 /PRNewswire/ -- A New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action. This development offers a new opportunity for investors to represent the class after the previously appointed lead...
(NASDAQ:SPPI) LOS ANGELES, Sept. 2, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. ("Spectrum " or "the Company") (NASDAQ: SPPI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
(NASDAQ:SPPI) LOS ANGELES, Sept. 2, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. ("Spectrum" or "the Company") (NASDAQ: SPPI) for violations of §§10(b) and 20(a) of the...
(NASDAQ:SPPI) NEW YORK, Aug. 29, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the "Class Period"), of the important...
NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the "Class Period"), of the important...
SAN DIEGO, Aug. 26, 2025 /PRNewswire/ -- Robbins LLP reminds investors who purchased shares of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) common stock between March 17, 2022 and September 22, 2022, of the reopening of the Lead Plaintiff appointment process in the pending securities...
PHILADELPHIA, Aug. 25, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum" or the "Company") on behalf of investors who purchased or otherwise acquired common...
NEW YORK, Aug. 19, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates...
PHILADELPHIA, Aug. 19, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum" or the "Company") on behalf of investors who purchased or otherwise acquired common...
LOS ANGELES, Aug. 18, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. ("Spectrum " or "the Company") (NASDAQ: SPPI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
NEW YORK, Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP announces the reopening of the Lead Plaintiff appointment process in a pending securities class action lawsuit on behalf of investors of Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI). Investors are advised...
LOS ANGELES, Aug. 14, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. ("Spectrum " or "the Company") (NASDAQ: SPPI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
LOS ANGELES, Aug. 14, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. ("Spectrum" or "the Company") (NASDAQ: SPPI) for violations of §§10(b) and 20(a) of the...
PHILADELPHIA, Aug. 13, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum" or the "Company") on behalf of investors who purchased or otherwise acquired common...
NEW YORK , Aug. 12, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates...
SPPI Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO, Aug. 12, 2025 /PRNewswire/ -- On August 4, 2025, the court overseeing the pending securities class action styled Christiansen v. Spectrum Pharmaceuticals, Inc., et al., No. 1:22-cv-10292 (S.D.N.Y.) re-opened the...
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers and acquirers of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) common stock between May 12, 2022 and September 22, 2022, both dates inclusive (the “Class Period”). The lead plaintiff process was reopened by the Court. Before and during the Class Period, Spectrum Pharmaceuticals purported to be a biopharmaceutical company focused on acquiring, devel
LOS ANGELES--(BUSINESS WIRE)---- $SPPI--Spectrum Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPPI
PHILADELPHIA, Aug. 6, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum" or the "Company") on behalf of investors who purchased or otherwise acquired common shares...
Spectrum Pharmaceuticals's (NASDAQ:SPPI) short percent of float has risen 14.81% since its last report. The company recently reported that it has 4.05 million shares sold short, which is 2.17% of all regular shares that are available for trading.
HC Wainwright & Co. has decided to maintain its Buy rating of Spectrum Pharmaceuticals (NASDAQ:SPPI) and raise its price target from $10.00 to $12.00. Shares of Spectrum Pharmaceuticals are trading up 5.79% over the last 24 hours, at $1.37 per share.
The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ: SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia.
